Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were 13.1 and 4.2 months,… More >

Xingliang Feng^*1, Meng Zhang^*†1, Jialin Meng^*, Yongqiang Wang^†, Yi Liu^*, Chaozhao Liang^*, Song Fan^*

Oncology Research, Vol.28, No.3, pp. 285-297, 2020, DOI:10.3727/096504020X15791676105394

Abstract We aimed to investigate the potential mechanisms of progression and identify novel prognosis-related biomarkers for papillary renal cell carcinoma (PRCC) patients. The related data were derived from The Cancer Genome Atlas (TCGA) and then analyzed by weighted gene coexpression network analysis (WGCNA). The correlation between each module and the clinical traits were analyzed by Pearson’s correlation analysis. Pathway analysis was conducted to reveal potential mechanisms. Hub genes within each module were screened by intramodule analysis, and visualized by Cytoscape software. Furthermore, important hub genes were validated in an external dataset and clinical samples. A total of 5,839 differentially expressed genes… More >

Ting La^*†, Lei Jin^*‡, Xiao Ying Liu^*, Ze Hua Song^*, Margaret Farrelly^†, Yu Chen Feng^†, Xu Guang Yan^†, Yuan Yuan Zhang^*,† Rick F. Thorne^*,*§ Xu Dong Zhang^*†, Liu Teng^*

Oncology Research, Vol.28, No.4, pp. 385-398, 2020, DOI:10.3727/096504020X15861709922491

Abstract The deubiquitinase cylindromatosis (CYLD) functions as a tumor suppressor inhibiting cell proliferation in many cancer types including melanoma. Here we present evidence that a proportion of melanoma cells are nonetheless addicted to CYLD for survival. The expression levels of CYLD varied widely in melanoma cell lines and melanomas in vivo, with a subset of melanoma cell lines and melanomas displaying even higher levels of CYLD than melanocyte lines and nevi, respectively. Strikingly, although short hairpin RNA (shRNA) knockdown of CYLD promoted, as anticipated, cell proliferation in some melanoma cell lines, it reduced cell viability in a fraction of melanoma cell… More >

Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with… More >

HUILI ZHU¹, LINA XIAO¹, XIA YIN¹, SHIBING XIANG¹, CHUNHUI WANG^2,*

BIOCELL, Vol.46, No.10, pp. 2241-2256, 2022, DOI:10.32604/biocell.2022.020389

Abstract Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous, making its prognosis prediction difficult. The arachidonic acid (AA) cascade is involved in carcinogenesis. Therefore, the metabolic enzymes of the AA cascade consist of lipoxygenases (LOXs), phospholipase A2s (PLA2s), and cyclooxygenases (COXs) along with their metabolic products, including leukotrienes. Nevertheless, the prognostic potential of AA metabolism-associated PDAC has not been explored. Herein, the mRNA expression patterns and the matching clinical information of individuals with PDAC were abstracted from online data resources. We employed the LASSO Cox regression model to develop a multigene clinical signature in the TCGA queue. The GEO queue and the… More >

Beifen Dai^1,#, Zhihao Xu^2,#, Hongjue Li³, Bo Wang³, Jinsong Cai¹, Xiaomo Liu^4,*

Oncologie, Vol.24, No.1, pp. 113-130, 2022, DOI:10.32604/oncologie.2022.020259

Abstract Large-scale genomic studies are important ways to comprehensively decode the human genomics, and provide valuable insights to human disease causalities and phenotype developments. Genomic studies are in need of high throughput bioinformatics analyses to harness and integrate such big data. It is in this overarching context that artificial intelligence (AI) offers enormous potentials to advance genomic studies. However, racial bias is always an important issue in the data. It is usually due to the accumulation process of the dataset that inevitability involved diverse subjects with different races. How can race bias affect the outcomes of AI methods? In this work,… More >

JUNXIA LIU¹, KE PANG², FEI HE^2,*

BIOCELL, Vol.46, No.7, pp. 1661-1673, 2022, DOI:10.32604/biocell.2022.018023

Abstract Breast cancer is one of the most common cancers in the world and seriously threatens the health of women worldwide. Prognostic models based on immune-related genes help to improve the prognosis prediction and clinical treatment of breast cancer patients. In the study, we used weighted gene co-expression network analysis to construct a co-expression network to screen out highly prognostic immune-related genes. Subsequently, the prognostic immune-related gene signature was successfully constructed from highly immune-related genes through COX regression and LASSO COX analysis. Survival analysis and time receiver operating characteristic curves indicate that the prognostic signature has strong predictive performance. And we… More >

Xiaodan He, Jingshi Wang, Zhao Wang^*

Oncologie, Vol.23, No.4, pp. 559-567, 2021, DOI:10.32604/oncologie.2021.018647

Abstract Despite extensive work-ups, some patients have been diagnosed with hemophagocytic lymphohistiocytosis (HLH) of unknown etiology. For HLH of unknown etiology, to investigate the clinical features and the factors that may affect the prognosis, we retrospectively reviewed the medical records of 94 patients hospitalized from January 2014 to December 2019. Survival times were evaluated until April 2020. For the 94 patients, the underlying causes of their diseases remained unclear at the end of the follow-up period, and the 1-, 3-, and 6-month survival rates, and the overall survival (OS) rates were 86.2%, 78.7%, 73.4%, and 70.2%, respectively. The multivariate analysis showed… More >

R. Sujatha¹, Jyotir Moy Chatterjee², NZ Jhanjhi³, Thamer A. Tabbakh⁴, Zahrah A. Almusaylim^5,*

Intelligent Automation & Soft Computing, Vol.32, No.1, pp. 115-129, 2022, DOI:10.32604/iasc.2022.019133

Abstract Heart failure (HF) is an intercontinental pandemic influencing in any event 26 million individuals globally and is expanding in commonness. HF healthiness consumptions are extensive and will increment significantly with a maturing populace. As per the World Health Organization (WHO), Cardiovascular diseases (CVDs) are the major reason for all-inclusive death, taking an expected 17.9 million lives per year. CVDs are a class of issues of the heart, blood vessels and include coronary heart sickness, cerebrovascular illness, rheumatic heart malady, and various other conditions. In the medical care industry, a lot of information is as often as possible created. Nonetheless, it… More >

ANZANA PARVIN^1,3, BANG-HONG WEI¹, SHUANG-LI HAO¹, WAN-XI YANG^1,*, FU-QING TAN^1,2,*

BIOCELL, Vol.45, No.5, pp. 1369-1391, 2021, DOI:10.32604/biocell.2021.016654

Abstract Mitotic kinesin KIFC1 plays critical roles in mitosis by regulating the spindle length, pole formation, and known for clustering extra centrosomes in cancer cells. Centrosome clustering is associated with the survival of cancer cells, but this phenomenon remains obscure in prostate cancer (PCa). The present study demonstrated that PCa cells showed centrosome amplification and clustering during interphase and mitosis, respectively. KIFC1 is highly expressed in PCa cells and tumor tissues of prostatic adenocarcinoma (PAC) patients. Up-regulation of KIFC1 facilitated the PCa cell survival in vitro by ensuring bipolar mitosis through clustering the multiple centrosomes, suggesting centrosome clustering could be a… More >